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Central vein stenosis is common because of the placement of venous access and
cardiac intravascular devices and compromises vascular access for dialysis. Endo-
vascular intervention with angioplasty and/or stent placement is the preferred
approach, but the results are suboptimal and limited. Primary patency after an-
gioplasty alone is poor, but secondary patency can be maintained with repeated
angioplasty. Stent placement is recommended for quick recurrence or elastic recoil
of stenosis. Primary patency of stents is also poor, though covered stents have
recently shown better patency than bare metal stents. Secondary patency requires
repeated intervention. Recanalization of occluded central veins is tedious and not
always successful. Placement of hybrid graft-catheter with a combined endovascular
surgical approach can maintain patency in many cases. In the presence of debili-
tating symptoms, palliative approach with endovascular banding or occlusion of the
access may be necessary. Prevention of central vein stenosis is the most desirable
strategy.
Copyright © 2015. The Korean Society of Nephrology. Published by Elsevier Ltd. This
is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Central veins are commonly injured as a result of placement
of intravascular devices and vascular access for a critical illness
and for performance of hemodialysis (HD). Nearly 80% of pa-
tients with end-stage renal disease in the United States initiate
dialysis using a catheter, and consequently, central vein injury
and subsequent restorative response leading to central vein
stenosis (CVS) are extremely common. Central veins are
generally obscured by the bony skeleton and are difﬁcult to
approach surgically. Hence, endovascular intervention with
angioplasty and/or stent placement becomes a logisticallymore
amenable approach for treatment of CVS. However, anatomi-
cally and functionally, central veins have several important
characteristics including the size, elasticity, curvature, andphrology, 395 W 12th
SA
garwal).
iety of Nephrology. Published
y-nc-nd/4.0/).amount of blood ﬂow that make treatment and maintenance of
their patency after intervention difﬁcult. This article will
describe approaches to endovascular intervention in different
clinical scenarios, which should be planned carefully.
Preintervention planning for CVS
There are several important considerations before formu-
lating a management plan for CVS.
Asymptomatic versus symptomatic CVS
This is a crucial considerationbeforeplanningan intervention
because central veins are more elastic and prone to recoil. An
intravascular ultrasound study showed immediate recoil in
>50% of central lesions [1]. Because of the elasticity of such le-
sions, stent placement is more likely to be required after an-
gioplasty. At present, the natural history of angioplasty and stent
placement are compromisedby frequent and rapid recurrence. Itby Elsevier Ltd. This is an open access article under the CC BY-NC-ND
Figure 1. KaplaneMeier curve of post-PTA primary patency duration
after angioplasty for CVS.
CVS, central vein stenosis; PTA, percutaneous angioplasty.
Note. From “Endovascular treatment of central venous stenoses in patients
with dialysis shunts”, by E. Buriankova, M. K€ocher, P. Bachleda, P. Utíkal, Z.
Kojecký, M. Cerna, M. Herman, 2003, Biomed Pap Med Fac Univ Palacky
Olomouc Czech Repub, 147, p. 203e206. Doi: 10.5507/bp.2003.030.
Copyright 2003, Biomedical Papers. Reprinted with permission.
Agarwal / Endovascular interventions for CVS 229is also possible that an asymptomatic lesion can become
symptomatic after the intervention. Indeed, stenosis has been
shown to progress faster after intervention [2]. Thirty-ﬁve
asymptomatic HD patients with arteriovenous (AV) graft and
>50% CVS underwent 86 venograms. Of the 28% of patients not
undergoing intervention, no one progressed to symptoms, stent
placement, or additional CVS.However, of the72%of thepatients
undergoing percutaneous angioplasty (PTA), 8% experienced
acceleration of CVS requiring further interventions. At the same
time, a rather high residual stenosis (40%) in the intervention
group was potentially indicative of worse prognosis to begin
with, making it difﬁcult to compare the 2 groups. Certainly, it is
possible that angioplasty can aggravate the venous response and
accelerate the stenotic process. The mechanism of angioplasty
itself involves cracking and ﬁssuring of the vessel intima which
can incite accelerated neointimal hyperplasia, and recurrent
lesions after angioplasty have been shown to have more
aggressive neointimal hyperplasia with higher proliferative in-
dex than the primary lesion [3]. Thus, higher elasticity and po-
tential for worse recurrent neointimal hyperplasia should deter
intervention in asymptomatic ormildly symptomatic CVS. These
patients require careful follow-up as worsening symptoms
would require intervention.
Availability of other access options
It is important to plan for a backup option in case the CVS
interventions were to fail. All available options should be
considered including reduction of access ﬂow, placement of
hybrid catheter graft, or surgical bypass if another potential site
for access placement is unavailable. Consideration of alternate
method of renal replacement therapy should always be a part of
the discussion.
Availability of local expertise and logistics for managing CVS
Complexity of CVS requires a multidisciplinary approach-
dranging from percutaneous to open intervention. Availability
of expertise will obviously deﬁne the ﬁnal approach. Formation
of a multidisciplinary team for discussion of challenging
vascular access cases will facilitate interaction of all practi-
tioners involved in the care of the patient. As newer technol-
ogies become available, it will be important to conduct clinical
trials that use standard criteria to deﬁne severity and outcome.
Endovascular intervention for CVS
Endovascular approaches to correction of CVS remain limited,
suboptimal, and possibly even detrimental in certain cases. As
mentioned earlier, more aggressive neointimal hyperplasia and
proliferative lesions were found in restenotic areas after angio-
plasty than in the original stenotic lesions [3]. Consequently,
endovascular intervention for CVS requires careful planning
while using restraint when clinically feasible and acceptable.
Percutaneous angioplasty
PTA with or without stent placement has been the recom-
mended preferred approach to CVS. The guideline 20 of Kidney
Disease Outcomes Quality Initiative (K/DOQI) suggests that the
percutaneous intervention with transluminal angioplasty is the
preferred treatment for CVS [4]. PTA has a very high initialtechnical success rates, ranging from 70% to 90% [5e11]. The
unassisted patency rates reported after PTA have varied from
23% to 63% at 6 months and cumulative patency rates from 29%
to 100%. At 12months, the unassisted patency rate after PTA has
ranged from12% to 50% and cumulative patency rate from13% to
100%. A more recent study using high-pressure balloons noted
better results with PTA alone, with unassisted patency rate of
60% at 6 months and 30% at 12 months (Fig. 1) [12]. It is to be
noted that the published studies in CVS used criteria that are not
uniform in reporting the description of lesion, severity, or
outcome and have been conducted in variable demographics
using variable technique and equipment with resultant wide
variationamong the results of these studies. Better results froma
secondmore recent study [10] also suggest presence of changing
variables. It is to be noted that the secondary patency can be
signiﬁcantly better with repeated angioplasty, evenwithout the
use of stent. It is also difﬁcult to compare PTA or stent placement
because of the reporting issues previously discussed.
There remain drawbacks of angioplasty approach to CVS
management. As mentioned, intravascular ultrasound study
after angioplasty of central veins has shown that central veins
are much more likely to recoil than the peripheral veins [1].
Thus, the success of PTA often depends on the elastic or
nonelastic nature of the lesion, which may have different
structural characteristics of the stenosis. In addition, acceler-
ated neointimal hyperplasia and faster progression of asymp-
tomatic lesions after angioplasty should curb the enthusiasm to
intervene in such lesions without signiﬁcant rationale [2,3].
Stents
Treatment of CVS is challenging, and stents for CVS were
used because of poor long-lasting results of PTA alone [13].
Guidelines for CVS recommend placement of a stent for elastic
recoil of the vein that leads to signiﬁcant residual stenosis after
PTA or for lesions recurring within 3 months after angioplasty
[4,14]. Self-expandable stents can be placed with a high degree
Kidney Res Clin Pract 34 (2015) 228e232230of technical success, and use of self-expanding metallic stents
for elastic lesions has been associated with better outcomes
than angioplasty alone.
Stents can be used in 2 scenarios:
1 Primary stent placement after PTA without waiting for
recurrence
Primary angioplasty (PTA) with primary stent placement (PTS)
has been considered in an attempt to improve short- and long-
term results. The outcomes of primary PTA and PTS were
compared at a tertiary referral academic medical center via a
retrospective analysis of database of consecutive HD patients
from 1995 to 2003 [11]. After primary high-pressure balloon
angioplasty, stenting (PTS) was used for failed or suboptimal
angioplasty in 26 patients with 26 CVS. PTA was done in 47 pa-
tients with 49 CVS. The stent group underwent 71 percutaneous
interventions per stenosis (average, 2.7 ± 2.4 interventions), and
the PTA groupunderwent 98 interventions per stenosis (average,
2.0 ± 1.6 interventions). Primary patency was equivalent be-
tween groups by KaplaneMeier analysis, with 30-day rates of
76% for both groups and 12-month rates of 29% for PTA and 21%
for PTS (P ¼ 0.48). Assisted primary patency was also equivalent
(P ¼ 0.08), with a 30-day patency rate of 81% and 12-month rate
of 73% for the PTA group versus PTS assisted patency rates of 84%
at 30 days and 46% at 12 months. Ipsilateral HD access survival
was equivalent between groups. The authors concluded that PTA
or PTS for CVS was safe, with low rates of technical failure,
requiredmultiple additional interventions, and neithermodality
offered durable outcomes. Furthermore, PTS did not improve on
the patency ratesmore than PTA and did not add to the longevity
of ipsilateral HD access sites. However, the study displays the
inherent dilemma of comparing patients who responded to PTA
and those who did not and underwent stent placement for that
reason. Inherent severityandnatureof resistant lesionsmake the
comparison of these populations difﬁcult and unfair. It is likely
that the lesions undergoing primary stenting would have suf-
fered early occlusion without stenting because of suboptimal
results, and the study could not provide a true comparison of
primary angioplasty with primary stenting of lesions that actu-
ally were successfully treated with PTA alone.
2 Stent placement after failure or recurrence of CVS
Stents are commonly used for difﬁcult or failed lesions with
angioplasty alone, and primary stenting is not common. The
technical success rates for stents are usually quite good. How-
ever, the primary and secondary patency of stents is limited,
probably because of the difﬁcult and more severe or recurrent
nature of the lesions requiring stent placement. Some initial
studies showed promisingly good results with the use of stain-
less steel stents [15]. However, other studies showed only
marginal results of such stents [16,17]. A recent retrospective
analysis of the nitinol shape memory alloy stents showed a
signiﬁcantly higher primary patency in central and peripheral
veins though a systematic study of such stents has not been
performed [18]. It is difﬁcult to compare results of studies done
over a period because stainless steel stents were used in earlier
studies and more advanced stents were used in the later study,
which may be responsible for better results. Irrespective of the
primary technical success, repeated interventions can provide a
signiﬁcantly longer assisted patency. This may be appropriate in
many clinical circumstances with end-stage vascular access.
In more recent literature, use of covered stents (also known
as stent grafts or endografts) has shown promise [19,20]. Thetechnical success rate is high, and primary and assisted patency
rates are signiﬁcantly better than the bare metal stents. The
graft material provides a relatively inert and stable matrix for
endothelialization, thereby reducing restenosis. The results in
salvaging occluded veins remainworse than the results of stent
placement in stenosed veins. Even though stents have limita-
tions (migration, fracture, intrastent neointimal hyperplasia,
and appearance of unrelated stenosis in the access circuit
leading to access failure), stent placement can provide an im-
mediate therapy for access salvage in difﬁcult cases.
The CVS related to the placement of cardiac rhythm devices
can be managed similar to CVS from other causes. Techniques
involve angioplasty, stent placement, or as a last resort, ligation of
access to reduce symptoms. Angioplasty has been shown to be
safe andprovidespoorprimarybut acceptable secondarypatency
rates at 1 year (Figs. 2A and B) [21]. When treating a device-
related CVS, placing stent to cover the lead wire is not recom-
mended to avoid trapping the wire. Angioplasty over the wire is
considered safe, but if stenting is needed, the device should be
removed and replaced after angioplasty and stent placement.
Epicardial leads represent an emerging alternative for patients
with advanced chronic kidney disease to preserve central veins.
Recanalization for occluded central veins
Central vein occlusion represents a catastrophic event, pre-
cluding use of that extremity for any type of access. It is not
uncommon to ﬁnd patients with severe stenosis or occlusion of
veins due to repeated and prolonged catheter placement while
attempting to create a functioning AV ﬁstula. In young patients
with central venous occlusion, it is worthwhile attempting to
recanalize the vein if an ipsilateral access is already in devel-
opment or is being considered for various reasons. A classic
hydrophilic wire approach may be successful at times, though
sharp recanalization with a needle that can be snared out from
the other side of the occlusion is often required. A radio-
frequency wire to recanalize occluded veins is another option.
As can be imagined, all such approaches of recanalization
would require stent placement to maintain the patency. Failure
to recanalize and recurrence of the lesion are common.
Frequent and multiple interventions to maintain patency are
generally required. Because of the complex nature of such oc-
clusions, the procedure can often result in complications and
should be performed with great caution.
Hybrid endovascular/surgical approach
In case of a refractory and recurrent stenosis, it is now
possible to maintain the patency of the central vein with a
hybrid graftecatheter device [22]. The graft portion of the de-
vice is anastomosed to the artery in the arm and connected to
the outﬂow provided by the catheter component that crosses
the treated stenosed portion of the central vein. This type of
access usually performs like an AV graft. The advantage of such
an access is primarily due to avoidance of an exteriorized
catheter thereby reducing rates of infection.
Endovascular intervention as a palliative approach
A high-ﬂow access can be especially detrimental in the
presence of inﬂoweoutﬂow mismatch because of CVS. Such
accesses can often continue towork without having to abandon
Figure 2. Primary (A) and secondary (B) patency after angioplasty of
central vein stenosis associated with cardiac rhythm devices [21].
Note. From “Patency rates for angioplasty in the treatment of pacemaker-
induced central venous stenosis in hemodialysis patients: results of a
multi-center study,” by A. Asif, L. Salman, R.G. Carrillo, J.D. Garisto,
G. Lopera, U. Barakat, O. Lenz, A. Yevzlin, A. Agarwal, F. Gadalean, B.
Sachdeva, T.J. Vachharajani, S. Wu, I.D. Maya, K. Abreo, 2009, Semin Dial, 22,
p. 671e676. Copyright 2009. Wiley. Reprinted with permission.
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in intravascular pressure and related symptoms. Balloon-
assisted banding with a goal of about 50% reduction of access
ﬂow has been used to reduce such symptoms [23].
When CVS remains refractory and symptomatic, sometimes
one has to resort to symptomatic and palliative approach to
reduce discomfort. For breast edema due to CVS, coil emboli-
zation of the long thoracic vein can be useful [24]. When the
access is no longer desirable, percutaneous ligation of access
can be done. Occlusion of access with a saline-ﬁlled balloon can
be attempted before resorting to surgical occlusion (Personal
communication. Gerald Beathard, MD).Challenges in endovascular intervention of CVS
It is important to consider limitations of our current
knowledge in endovascular intervention for CVS. Better un-
derstanding and development of equipment and angioplasty
technique to reduce endovascular injury and postoperative
methods of modulating endovascular response will transform
this area of unmet need. Despite advances, the primaryapproach to CVS should be prevention of CVS by avoiding
endovascular injury.Conﬂicts of interest
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